adverse

Domperidone (R33812) 是多巴胺 2 受体拮抗剂，能够影响胃和小肠的化学感受器触发区和运动功能，具有止吐和促动力作用。

Carbidopa (Lodosyn) 是一种选择性芳香烃受体(AhR)调节剂，是外周型脱羧酶抑制剂，抑制胰腺癌细胞和肿瘤生长，可用于帕金森病的研究。

Levobupivacaine 是一种氨基酰胺类局麻药，属于n-alkylsubstituted pipecoloxylidide 家族。它是bupivacaine 的 S-对映异构体。

Phenindione (Rectadione) 是一种茚满二酮，已被用作抗凝剂，可作为维生素 K 拮抗剂。它的作用类似于华法林，但由于其严重不良反应的发生率较高，现在很少使用。

3,3',4,4'-Benzophenonetetracarboxylic dianhydride 是一种化合物，用于生产聚酰亚胺薄膜和粘合剂的聚酰亚胺前体。它是一种无毒材料，对人体健康没有已知的不良影响。

Gamabufotalin (Gamabufagin) 是一种蟾蜍甾烯，存在于蟾酥中。它稳定性高，毒性低，被广泛用于癌症的研究。

Hydroxocobalamin acetate 是可注射的天然维生素 B12，其不良反应特征良好，可用于研究维生素 B12 缺乏症 (包括恶性贫血) 。

LJ-2698作为一种腺苷A3受体拮抗剂，目前正在研究用于治疗肺气肿和DKD（Diabetic Kidney Disease）。在小鼠肺模型中，LJ-2698能有效减轻由弹性蛋白酶引起的负面影响，同时抑制基质金属蛋白酶的活性和细胞凋亡。此外，LJ-2698在治疗糖尿病肾病方面的应用也得到了探索，已在小鼠中成功预防了多种类型的肾损伤。

Dibutyl Phthalate-d4 是 Dibutyl Phthalate 的氘代化合物。Dibutyl Phthalate 的 CAS 号为 84-69-5。Dibutyl phthalate 是一种用于大多数塑料的增塑剂，存在于水、空气、土壤、植物和动物中。长期接触可能会产生一些不利影响。

MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy. IC50 value: 1 nM (hSCD1) Target: SCD1 in vitro: MK-8245, a phenoxy piperidine isoxazole derivative, has been identified as a potent and liver-specific SCD inhibitor. It contains a tetrazole acetic acid moiety, which is the key molecule for OATPs recognition and liver-targeting. MK-8245 displays similar potencies against human, rat and mouse SCD1 with IC50 values of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1. MK-8245 exhibits a significant SCD inhibition in the rat hepatocyte assay which contains functional, active OATPs with IC50 of 68 nM, while being only weakly active in the HepG2 cell assay which is devoid of active OATPs with IC50 of ~1 μM. MK-8245 displays highly selective activity for the Δ-5 and Δ-6 desaturases (i.e., >100000 μM vs rat and human Δ5D and Δ6D as assessed in the HepG assay. in vivo: Administration of MK-8245 at 10 mg kg in mice exhibits a tissue distribution profile concentrated in the liver. It shows a liver-to-Harderian gland ratio of 21, suggesting a high degree of liver-targeting compared to a systemically distributed compound with liver-to-Harderian gland ratio of 1.5. Oral dosing of MK-8245 in mice, rats, dogs, and rhesus monkeys demonstrates that MK-8245 is distributed mainly to the liver, with low exposure in tissues associated with potential adverse events. The liver-to-skin ratios are >30:1 in all four species. Administration of MK-8245 to eDIO mice before the glucose challenge improves glucose clearance in a dose-dependent manner with ED50 of 7 mg kg.

CAY10711 is a substituted diamine that produces rapid bactericidal activity against both Gram-positive and Gram-negative bacteria, including methicillin-resistant S. aureus (MRSA) and stationary-phase bacteria. It displays MIC99 values of 2.9, 11.5, 2.9, and 2.9 μM against S. aureus RN4220, P. aeruginosa PAO1, E. coli ANS1, and MRSA 10082B, respectively. CAY10711 reduces biofilm formation and promotes biofilm dispersal in P. aeruginosa. It is synergistic with kanamycin and has limited adverse effects against mammalian cells or C. elegans development, survival, or reproduction.

PPARγ agonist 1 是 PPARγ 的有效激动剂，能够高效的激活 hPPARγ ，并不引起完全激动，进而能够避免不良反应。PPARγ agonist 1 对代谢紊乱相关心血管疾病表现出研究潜力。

DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK. This compound exerts a synergistic effect when combined with radiotherapy and chemotherapy, resulting in enhanced therapeutic outcomes and significant inhibition of tumor growth. Furthermore, DNA-PK-IN-3 demonstrates remarkable efficacy in reducing damage to normal cells, effectively minimizing adverse side effects. Due to these compelling properties, DNA-PK-IN-3 holds great potential for cancer research applications[1].

FAK-IN-3 是一种有效的粘着斑激酶 (FAK) 抑制剂。FAK-IN-3 能够减少 PA-1 细胞的迁移和侵袭，并抑制 MMP-2 和 MMP-9 的表达。FAK-IN-3 对肿瘤生长和转移具有抑制作用，且没有明显不良反应。FAK-IN-3 对卵巢癌表现出研究潜力。

WAY-639872是一种用于生化反应研究的活性分子。

Cerlapirdine, also known as SAM-531, WAY-262,531 and PF-05212365, is a selective, potent, full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine has been in clinical development for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. As of 2011, it is in phase II clinical trials, and has demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events. It exerts its effects by acting as a selective 5-HT6 receptor antagonist.

Cecropin A (1-7)-Melittin A (2-9) 为一种具抗菌效能的肽，对广谱革兰氏阳性及革兰氏阴性需氧菌显示出显著的抗菌活性，同时展现出抗疟能力，而无蜂毒肽所致的不良溶血现象。

NBI-921352 (XEN901) 是一种有效的钠通道抑制剂，专门针对 Nat 1.6通道。NBI-921352 (XEN901) 可有效治疗癫痫引起的神经系统病变，而不会引起严重不良反应。

Abivertinib, also known as AC0010 and Avitinib, is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor that demonstrated clinical efficacy and manageable adverse events (AEs). Abivertinib inhibits cell proliferation, reduces colony-forming capacity, and induces apoptosis and cell cycle arrest in AML cells, especially those harboring FLT3-ITD mutations. Abivertinib was also found to be more sensitive than ibrutinib in treating AML. Abivertinib may be a promising novel agent for AML, with potential for combination treatment with HHT.

NU5455 是一种选择性的、有效的、口服具有活力的 DNA-PKcs 抑制剂。NU5455 能够提高肝肿瘤异种移植物中局部释放的多柔比星的效果，且不引起任何不良反应。NU5455 能够提高肠胃外给药的拓扑异构酶抑制剂的功效和毒性。

V11294A is a novel PDE4 inhibitor. A single oral 300 mg dose of V11294A administered to healthy volunteers results in plasma concentrations adequate to inhibit activation of inflammatory cells ex vivo, which persists for at least 24 h without any adverse reactions

Clozapine HCl is a tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A 2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.

DS-6930 是一种有效的和选择性的 PPARγ激动剂（EC50= 41 nM）。DS-6930 可有效降低血浆葡萄糖 (PG)水平，此外，与 Rosiglitazone 相比，具有更少的 PPARγ 相关不良反应。DS-6930 在糖尿病中具有研究价值。

TLR9-IN-1 是一种选择性的、有效的 TLR9 抑制剂，能够作用于人 TLR9 (IC50: 7 nM)。TLR9-IN-1 能够用于不良免疫应答相关疾病的研究。